Davidson Capital Management Inc. Abb Vie Inc. Transaction History

Davidson Capital Management Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 08, 2024	BUY	$137.6 - $154.97 $7,430 - $8,368	54 New	54 $8,000
Q1 2023 May 01, 2023	SELL	$144.61 - $166.54 $6,362 - $7,327	-44 Reduced 0.45%	9,664 $1.54 Million
Q4 2022 Feb 07, 2023	SELL	$138.31 - $165.87 $4,702 - $5,639	-34 Reduced 0.35%	9,708 $1.57 Million
Q3 2022 Nov 09, 2022	BUY	$134.21 - $153.93 $99,986 - $114,677	745 Added 8.28%	9,742 $1.31 Million
Q2 2022 Aug 17, 2022	SELL	$137.62 - $174.96 $3,165 - $4,024	-23 Reduced 0.25%	8,997 $1.38 Million
Q1 2022 May 17, 2022	SELL	$131.98 - $163.75 $337,604 - $418,872	-2,558 Reduced 22.09%	9,020 $1.46 Million
Q4 2021 Feb 02, 2022	BUY	$107.43 - $135.93 $39,856 - $50,430	371 Added 3.31%	11,578 $1.57 Million
Q3 2021 Nov 10, 2021	BUY	$106.4 - $120.78 $42,347 - $48,070	398 Added 3.68%	11,207 $1.21 Million
Q2 2021 Aug 10, 2021	BUY	$105.21 - $117.21 $10,836 - $12,072	103 Added 0.96%	10,809 $1.22 Million
Q1 2021 May 10, 2021	BUY	$102.3 - $112.62 $1.1 Million - $1.21 Million	10,706 New	10,706 $1.16 Million

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Davidson Capital Management Inc., based on Form 13F filings with the SEC.

Stay updated on Davidson Capital Management Inc. with notifications on news.